Meeting Banner
Abstract #3824

Gadolinium-free extracellular MR contrast agent for tumor imaging

Joris Tchouala Nofiele 1 , Inga E Haedicke 2 , Yong Le Zhu 2 , Xiao-an Zhang 2 , and Hai-Ling Margaret Cheng 1,3

1 Hospital for Sick Children, Toronto, Ontario, Canada, 2 Chemistry, University of Toronto, Toronto, Ontario, Canada, 3 Institute of Biomaterials & Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada

Contrast administration is integral to tumor diagnostic imaging, and gadolinium (Gd)-based contrast agents are the current approved standard for clinical workflow. However, a number of patients, particularly those with impaired kidney function, are exempt from the benefits of a contrast-enhanced examination. In this study, we investigate the potential of a recently described novel extracellular and renally filtered manganese porphyrin T1 agent for tumor imaging. Results in tumor-bearing rats demonstrate that the new agent, MnTCP, exhibits similar pharmacokinetics but provides consistently greater enhancement than Gd-DTPA. MnTCP can potentially provide contrast-enhanced MRI for tumor diagnosis in a broader patient base.

This abstract and the presentation materials are available to members only; a login is required.

Join Here